Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical firm, announced it will provide business updates and report third-quarter financial results on November 7, 2022, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical firm, announced it will provide business updates and report third-quarter financial results on November 7, 2022, at 8:00 a.m. ET. A conference call will be held, accessible via dial-in or live webcast on the company’s website. Mersana specializes in antibody-drug conjugates (ADCs) aimed at addressing high unmet needs in cancer treatment, with key candidates like upifitamab rilsodotin (UpRi) in pivotal trials for ovarian cancer. The company is also developing other ADCs and has collaborations underway.
Details
News Market Reaction – MRSN
The recorded move for MRSN in the trading session of this news was +9.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the third quarter ended September 30, 2022 on Monday, November 7, 2022 and will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 646-307-1963 (domestic) or 800-715-9871 (international) and provide the Conference ID 9941053. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.